Guanosine, 5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-hexadecyl-N-(2-methyl-1-oxopropyl)-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] manufacturers
|
| | Guanosine, 5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-hexadecyl-N-(2-methyl-1-oxopropyl)-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] Basic information |
| | Guanosine, 5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-hexadecyl-N-(2-methyl-1-oxopropyl)-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] Chemical Properties |
| | Guanosine, 5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-hexadecyl-N-(2-methyl-1-oxopropyl)-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] Usage And Synthesis |
| Uses | N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | Guanosine, 5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-hexadecyl-N-(2-methyl-1-oxopropyl)-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] Preparation Products And Raw materials |
|